Health Care & Life Sciences » Biotechnology | Advaxis Inc.

Advaxis Inc. | Income Statement

Fiscal year is November-October. All values USD Thousands.
2013
2014
2015
2016
2017
2018
Sales/Revenue
-
1,000.00
-
3,994.90
12,031.10
6,063
Cost of Goods Sold (COGS) incl. D&A
178.60
-
265.40
-
-
-
Gross Income
178.60
-
265.40
-
-
-
SG&A Expense
14,515.00
20,335.30
48,405.30
79,950.90
109,123.10
73,280
EBIT
14,693.60
19,538.60
48,670.70
76,492.20
98,212.50
68,718
Unusual Expense
4,959.80
625.30
49.00
69.10
295.20
2,353
Non Operating Income/Expense
76.30
36.30
28.50
0.20
0.10
677
Interest Expense
987.70
5.30
6.60
-
-
-
Pretax Income
20,712.00
18,882.20
48,640.50
76,091.90
97,838.10
66,465
Income Tax
725.20
2,356.90
1,609.30
2,535.60
4,402.70
50
Consolidated Net Income
19,986.80
16,525.30
47,031.10
73,556.20
93,435.40
66,515
Net Income
19,986.80
16,525.30
47,031.10
73,556.20
93,435.40
66,515
Net Income After Extraordinaries
19,986.80
16,525.30
47,031.10
73,556.20
93,435.40
66,515
Net Income Available to Common
20,541.80
16,525.30
47,031.10
73,556.20
93,435.40
66,515
EPS (Basic)
4.10
0.97
1.68
2.08
2.31
19.36
Basic Shares Outstanding
5,012.10
17,106.60
28,026.20
35,401.00
40,527.80
3,434.80
EPS (Diluted)
4.10
0.97
1.68
2.08
2.31
19.36
Diluted Shares Outstanding
5,012.10
17,106.60
28,026.20
35,401.00
40,527.80
3,434.80
EBITDA
14,515.00
19,335.30
48,405.30
75,956.10
97,092.10
67,217
Non-Operating Interest Income
5.40
-
114.20
331.50
669.80
577
Preferred Dividends
555.00
-
-
-
-
-

About Advaxis

View Profile
Address
305 College Road East
Princeton New Jersey 08540
United States
Employees -
Website http://www.advaxis.com
Updated 07/08/2019
Advaxis, Inc. is a biotechnology company, which engages in the discovery, development, and commercialization of cancer immunotherapies. It manages platform technology that utilizes live attenuated Listeria monocytogenes bioengineered to secrete antigen or adjuvant fusion proteins. It has four franchises in various stages of clinical and pre-clinical development, namely: HPV-associated cancers, prostate cancer, neoantigen therapy, and hotspot mutation therapy.

StatInvestor

Privacy Policy
Feedback

© 2024 StatInvestor All Rights Reserved.